# A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

> **NCT06244316** · PHASE2 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 317 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** rhNGF 5 μg/mL
- **DRUG:** rhNGF 10 μg/mL
- **DRUG:** Vehicle (Placebo solution)

## Key facts

- **NCT ID:** NCT06244316
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-22
- **Primary completion:** 2024-12-04
- **Final completion:** 2024-12-04
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06244316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06244316, "A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06244316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*